Next generation kinase inhibitors
with unique properties
Potent and selective Nanocyclix leads for known
and novel kinases.
New partnering opportunity: Nanocyclix RIPK2 inhibitors
for use in auto-immune diseases
Pave the way for a truly personalized approach in cancer.
Translational biomarker approaches
to address patient needs
Pharmaco-imaging in support of therapeutic development
and for drug targeting.
State-of-the-art models for optimal
Patient-derived xenografts and human immune system
models to allow better decisions.
We partner to advance cancer
Creative partnerships to drive development for oncology
and other serious illnesses with no known effective treatment.
A large panel of technological and scientific solutions for pharmacological qualification of your compounds : a unique oncology preclinical CRO
A platform-based approach for the discovery of novel chemical entities with therapeutic and diagnostic potential